| Year |
Citation |
Score |
| 2022 |
Semb AG, Ikdahl E, Kerola AM, Wibetoe G, Sexton J, Crowson CS, van Riel P, Kitas G, Graham I, Rollefstad S. A Clinical Audit of Cardiovascular Risk Factors and Disease in Patients with Rheumatoid Arthritis - SURF-RA. Mediterranean Journal of Rheumatology. 33: 201-217. PMID 36128215 DOI: 10.31138/mjr.33.2.201 |
0.332 |
|
| 2022 |
Semb AG, Rollefstad S, Sexton J, Ikdahl E, Crowson CS, van Riel P, Kitas G, Graham I, Kerola AM. Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit. International Journal of Cardiology. Heart & Vasculature. 42: 101117. PMID 36118256 DOI: 10.1016/j.ijcha.2022.101117 |
0.309 |
|
| 2020 |
Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Blaas E, Senolt L, Szekanecz Z, Choy E, Dougados M, Jacobs JW, Geenen R, ... ... van Riel P, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases. PMID 33004335 DOI: 10.1136/annrheumdis-2020-217344 |
0.39 |
|
| 2017 |
Crowson CS, Gabriel SE, Semb AG, van Riel PL, Karpouzas G, Dessein PH, Hitchon C, Pascual-Ramos V, Kitas GD. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology (Oxford, England). PMID 28339992 DOI: 10.1093/rheumatology/kex038 |
0.314 |
|
| 2017 |
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, ... ... van Riel P, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases. PMID 28264816 DOI: 10.1136/Annrheumdis-2016-210715 |
0.315 |
|
| 2016 |
van Riel PL, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clinical and Experimental Rheumatology. 34: 40-44. PMID 27762189 |
0.36 |
|
| 2016 |
Hendrikx J, de Jonge MJ, Fransen J, Kievit W, van Riel PL. Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis. Rmd Open. 2: e000202. PMID 27651921 DOI: 10.1136/rmdopen-2015-000202 |
0.339 |
|
| 2016 |
Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry. The Journal of Rheumatology. PMID 27481900 DOI: 10.3899/jrheum.151014 |
0.327 |
|
| 2016 |
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, et al. Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Research & Therapy. 18: 144. PMID 27324256 DOI: 10.1186/s13075-016-1048-4 |
0.336 |
|
| 2016 |
Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD. Cardiovascular screening in patients with Rheumatoid Arthritis is cost-effective. Arthritis Care & Research. PMID 27159060 DOI: 10.1002/acr.22929 |
0.309 |
|
| 2016 |
Rongen-van Dartel SA, Repping-Wuts H, Donders R, van Hoogmoed D, Knoop H, Bleijenberg G, van Riel PL, Fransen J. A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis. Clinical and Experimental Rheumatology. PMID 27049923 |
0.307 |
|
| 2016 |
Steunebrink LM, Versteeg GA, Vonkeman HE, Ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PL, van de Laar MA. Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry. Arthritis Research & Therapy. 18: 60. PMID 26956382 DOI: 10.1186/s13075-016-0962-9 |
0.372 |
|
| 2016 |
Moghadam MG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, et al. Stopping Tumor Necrosis Factor-inhibitors in Patients with Established Rheumatoid Arthritis in Remission or Stable Low Disease Activity: A Pragmatic Randomized Multicenter Open-Label Controlled Trial. Arthritis & Rheumatology (Hoboken, N.J.). PMID 26866428 DOI: 10.1002/art.39626 |
0.394 |
|
| 2016 |
Steunebrink LM, Vonkeman HE, Ten Klooster PM, Hoekstra M, van Riel PL, van de Laar MA. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry. Clinical Rheumatology. PMID 26852313 DOI: 10.1007/s10067-016-3191-3 |
0.411 |
|
| 2015 |
Santegoets KC, Wenink MH, Braga FA, Cossu M, Lamers-Karnebeek FB, van Riel PL, Sturm PD, van den Berg WB, Radstake TR. Impaired Porphyromonas gingivalis induced TNFα production by dendritic cells typifies patients with rheumatoid arthritis. Arthritis & Rheumatology (Hoboken, N.J.). PMID 26606260 DOI: 10.1002/art.39514 |
0.361 |
|
| 2015 |
Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W. Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. Rmd Open. 1: e000147. PMID 26535151 DOI: 10.1136/rmdopen-2015-000147 |
0.39 |
|
| 2015 |
Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial. Arthritis Research & Therapy. 17: 134. PMID 25997746 DOI: 10.1186/s13075-015-0630-5 |
0.366 |
|
| 2015 |
de Punder YM, Jansen TL, van Ede AE, den Broeder AA, van Riel PL, Fransen J. Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model. The Journal of Rheumatology. 42: 398-404. PMID 25593241 DOI: 10.3899/jrheum.140085 |
0.351 |
|
| 2015 |
Oude Voshaar MA, Ten Klooster PM, Bode C, Vonkeman HE, Glas CA, Jansen T, van Albada-Kuipers I, van Riel PL, van de Laar MA. Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures. The Journal of Rheumatology. 42: 413-20. PMID 25593225 DOI: 10.3899/jrheum.140389 |
0.338 |
|
| 2015 |
Manders SH, Kievit W, Adang E, Jansen TJ, Stolk JN, Visser H, Schilder AM, Vonkeman HE, van de Laar MA, van Riel PL. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. Annals of the Rheumatic Diseases. 74: e24. PMID 25480886 DOI: 10.1136/annrheumdis-2014-207005 |
0.344 |
|
| 2015 |
van Lümig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, Fransen J, Kievit W, de Jong EM. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. Journal of the European Academy of Dermatology and Venereology : Jeadv. 29: 752-60. PMID 25229823 DOI: 10.1111/jdv.12675 |
0.314 |
|
| 2015 |
Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 74: 998-1003. PMID 24458537 DOI: 10.1136/annrheumdis-2013-204531 |
0.342 |
|
| 2015 |
Lamers-Karnebeek F, Jansen T, van Riel P, Luime J, Jacobs J. OP0181 Ultrasonography as Predictor for Flare in Rheumatoid Arthritis Patients with Low Disease Activity: Nine Month Results from Poet-Us-Study Annals of the Rheumatic Diseases. 74: 140.1-140. DOI: 10.1136/ANNRHEUMDIS-2015-EULAR.5185 |
0.363 |
|
| 2015 |
Manders S, van de Laar M, Rongen-van Dartel S, Bos R, Visser H, Brus H, Jansen T, Vonkeman H, van Riel P, Kievit W. FRI0345 Tapering MTX in Patients with RA Using TNFI Treatment is Possible: Table 1. Annals of the Rheumatic Diseases. 74: 550.2-550. DOI: 10.1136/annrheumdis-2015-eular.1606 |
0.394 |
|
| 2014 |
Siemons L, Ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. Bmc Musculoskeletal Disorders. 15: 368. PMID 25373740 DOI: 10.1186/1471-2474-15-368 |
0.319 |
|
| 2014 |
Umi?evi? Mirkov M, Janss L, Vermeulen SH, van de Laar MA, van Riel PL, Guchelaar HJ, Brunner HG, Albers CA, Coenen MJ. Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. PMID 25114059 DOI: 10.1136/Annrheumdis-2014-205541 |
0.321 |
|
| 2014 |
Tran-Duy A, Boonen A, Kievit W, van Riel PL, van de Laar MA, Severens JL. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. Pharmacoeconomics. 32: 1015-28. PMID 24972589 DOI: 10.1007/s40273-014-0184-4 |
0.372 |
|
| 2014 |
Manders SH, Kievit W, Braakman-Jansen AL, Brus HL, Hendriks L, Fransen J, van de Laar MA, van Riel PL. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors. The Journal of Rheumatology. 41: 1263-9. PMID 24833758 DOI: 10.3899/jrheum.130878 |
0.326 |
|
| 2014 |
Oude Voshaar MA, ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA. Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis. Plos One. 9: e92367. PMID 24637885 DOI: 10.1371/journal.pone.0092367 |
0.33 |
|
| 2014 |
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, ... ... van Riel PL, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 506: 376-81. PMID 24390342 DOI: 10.1038/Nature12873 |
0.303 |
|
| 2014 |
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, ... ... van Riel PL, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases. 73: 492-509. PMID 24161836 DOI: 10.1136/annrheumdis-2013-204573 |
0.35 |
|
| 2014 |
Cutolo M, Kitas GD, van Riel PL. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Seminars in Arthritis and Rheumatism. 43: 479-88. PMID 24080116 DOI: 10.1016/j.semarthrit.2013.08.004 |
0.357 |
|
| 2013 |
Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, den Broeder AA, van Riel PL, Fransen J, van de Laar MA. Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. Bmc Musculoskeletal Disorders. 14: 350. PMID 24330489 DOI: 10.1186/1471-2474-14-350 |
0.308 |
|
| 2013 |
de Punder YM, Hendrikx J, den Broeder AA, Valls Pascual E, van Riel PL, Fransen J. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative. The Journal of Rheumatology. 40: 1268-74. PMID 23729803 DOI: 10.3899/jrheum.121438 |
0.358 |
|
| 2013 |
Kievit W, Fransen J, de Waal Malefijt MC, den Broeder AA, van Riel PL. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford, England). 52: 1500-8. PMID 23657913 DOI: 10.1093/rheumatology/ket166 |
0.398 |
|
| 2013 |
van den Bemt BJ, den Broeder AA, Wolbink GJ, van den Maas A, Hekster YA, van Riel PL, Benraad HB, van den Hoogen FH. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. British Journal of Clinical Pharmacology. 76: 939-45. PMID 23601129 DOI: 10.1111/bcp.12142 |
0.335 |
|
| 2013 |
Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, ... ... van Riel PL, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. Plos Genetics. 9: e1003394. PMID 23555300 DOI: 10.1371/Journal.Pgen.1003394 |
0.338 |
|
| 2013 |
Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, van der Bijl AE, van Riel PL, van de Laar MA. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort. Arthritis Care & Research. 65: 1219-26. PMID 23436821 DOI: 10.1002/acr.21984 |
0.378 |
|
| 2013 |
Umiċeviċ Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR, Lee AT, Huizinga TW, Allaart R, Barton A, Mariette X, Miceli CR, Criswell LA, Tak PP, de Vries N, ... ... van Riel PL, et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 72: 1375-81. PMID 23233654 DOI: 10.1136/Annrheumdis-2012-202405 |
0.377 |
|
| 2013 |
van der Maas A, Lie E, Christensen R, Choy E, de Man YA, van Riel P, Woodworth T, den Broeder AA. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Annals of the Rheumatic Diseases. 72: 1800-5. PMID 23178206 DOI: 10.1136/annrheumdis-2012-202281 |
0.349 |
|
| 2013 |
van Hoogmoed D, Fransen J, Repping-Wuts H, Spee L, Bleijenberg G, van Riel PL. The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients. Scandinavian Journal of Rheumatology. 42: 15-9. PMID 22992002 DOI: 10.3109/03009742.2012.709878 |
0.41 |
|
| 2013 |
van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals of the Rheumatic Diseases. 72: 895-900. PMID 22887849 DOI: 10.1136/annrheumdis-2012-201338 |
0.307 |
|
| 2013 |
Siemons L, Ten Klooster PM, Taal E, Kuper IH, van Riel PL, Glas CA, van de Laar MA. Contribution of assessing forefoot joints in early rheumatoid arthritis patients: insights from item response theory. Arthritis Care & Research. 65: 212-9. PMID 22807101 DOI: 10.1002/acr.21795 |
0.302 |
|
| 2013 |
Ferwerda M, Spillekom S, van Middendorp H, van Beugen S, Kievit W, Fransen J, Visser H, van Oijen P, Taal E, van Riel P, de Jong E, van de Kerkhof P, van der Laar M, Evers A. THU0590 The Patient-Therapist Relationship as An Indicator for Treatment Success in E-Health Treatments for Patients with Rheumatoid Arthritis and Psorias Annals of the Rheumatic Diseases. 72: A364.2-A364. DOI: 10.1136/annrheumdis-2013-eular.1118 |
0.319 |
|
| 2013 |
Manders S, Kievit W, Braakman A, Hendriks L, Brus H, Fransen J, van de Laar M, van Riel P. SAT0481 Are TNF blocking agents associated with changes in work participation in patients with RA?: Annals of the Rheumatic Diseases. 71: 635.2-635. DOI: 10.1136/ANNRHEUMDIS-2012-EULAR.3427 |
0.316 |
|
| 2013 |
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U, Ancuta I, Pavelka K, Nordström D, Gabay C, Canhao H, Tomsic M, van Riel P, Gomez-Reino J, Kvien T, et al. OP0028 Efficacy of different doses of rituximab for the treatment of RA: Data from the cererra collaboration Annals of the Rheumatic Diseases. 71: 62.2-62. DOI: 10.1136/annrheumdis-2012-eular.1711 |
0.332 |
|
| 2012 |
Toonen EJ, Barrera P, Fransen J, de Brouwer AP, Eijsbouts AM, Miossec P, Marotte H, Scheffer H, van Riel PL, Franke B, Coenen MJ. Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis. Arthritis Research & Therapy. 14: R264. PMID 23217265 DOI: 10.1186/ar4110 |
0.328 |
|
| 2012 |
Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, van de Laar MA. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Research & Therapy. 14: R254. PMID 23176083 DOI: 10.1186/ar4099 |
0.363 |
|
| 2012 |
Popa CD, Arts E, Fransen J, van Riel PL. Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicals. Mediators of Inflammation. 2012: 785946. PMID 22991486 DOI: 10.1155/2012/785946 |
0.308 |
|
| 2012 |
Fransen J, Kooloos WM, Wessels JA, Huizinga TW, Guchelaar HJ, van Riel PL, Barrera P. Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics. 13: 1087-94. PMID 22838954 DOI: 10.2217/pgs.12.83 |
0.313 |
|
| 2012 |
Keystone EC, Smolen J, Van riel P. Developing an effective treatment algorithm for rheumatoid arthritis Rheumatology (United Kingdom). 51: v48-v54. PMID 22718927 DOI: 10.1093/rheumatology/kes122 |
0.363 |
|
| 2012 |
de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, van Riel PL. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford, England). 51: 1610-7. PMID 22539487 DOI: 10.1093/rheumatology/kes078 |
0.36 |
|
| 2012 |
van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases. 71: 1849-54. PMID 22504561 DOI: 10.1136/annrheumdis-2011-200945 |
0.359 |
|
| 2012 |
Toonen EJ, Gilissen C, Franke B, Kievit W, Eijsbouts AM, den Broeder AA, van Reijmersdal SV, Veltman JA, Scheffer H, Radstake TR, van Riel PL, Barrera P, Coenen MJ. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. Plos One. 7: e33199. PMID 22457743 DOI: 10.1371/journal.pone.0033199 |
0.309 |
|
| 2012 |
Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, van Riel PL, van de Laar MA. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford, England). 51: 1076-80. PMID 22302059 DOI: 10.1093/rheumatology/ker425 |
0.391 |
|
| 2012 |
Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, Van Riel P, Fransen J, Van De Laar MAFJ. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: A study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry Annals of the Rheumatic Diseases. 71: 845-850. PMID 22210852 DOI: 10.1136/annrheumdis-2011-200274 |
0.373 |
|
| 2012 |
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Annals of the Rheumatic Diseases. 71: 374-7. PMID 21972242 DOI: 10.1136/annrheumdis-2011-200003 |
0.342 |
|
| 2011 |
Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. The Journal of Rheumatology. 38: 2355-61. PMID 21885487 DOI: 10.3899/jrheum.101324 |
0.329 |
|
| 2011 |
van Hulst LT, Kievit W, van Bommel R, van Riel PL, Fraenkel L. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care & Research. 63: 1407-14. PMID 21748861 DOI: 10.1002/acr.20551 |
0.347 |
|
| 2011 |
Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis and Rheumatism. 63: 2865-72. PMID 21647867 DOI: 10.1002/art.30494 |
0.376 |
|
| 2011 |
Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases. 70: 1575-80. PMID 21571731 DOI: 10.1136/ard.2010.148759 |
0.385 |
|
| 2011 |
Schipper LG, Kievit W, den Broeder AA, van der Laar MA, Adang EM, Fransen J, van Riel PL. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford, England). 50: 1320-30. PMID 21371999 DOI: 10.1093/rheumatology/ker084 |
0.306 |
|
| 2011 |
Snijders GF, den Broeder AA, van Riel PL, Straten VH, de Man FH, van den Hoogen FH, van den Ende CH. Evidence-based tailored conservative treatment of knee and hip osteoarthritis: between knowing and doing. Scandinavian Journal of Rheumatology. 40: 225-31. PMID 21261551 DOI: 10.3109/03009742.2010.530611 |
0.306 |
|
| 2011 |
Dawidowicz K, Allanore Y, Guedj M, Pierlot C, Bombardieri S, Balsa A, Westhovens R, Barrera P, Alves H, Teixeira VH, Petit-Teixeira E, van de Putte L, van Riel P, Prum B, Bardin T, et al. The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype. Annals of the Rheumatic Diseases. 70: 117-21. PMID 20980283 DOI: 10.1136/ard.2010.129171 |
0.529 |
|
| 2011 |
Arts EE, Jansen TL, Den Broeder A, Vonkeman HE, Dutmer E, Van de Laar MA, Van Riel PL, Fransen J. Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Annals of the Rheumatic Diseases. 70: 877-8. PMID 20956405 DOI: 10.1136/ard.2010.136093 |
0.341 |
|
| 2011 |
Schipper LG, van Riel PL. Ups and downs in the treatment strategies of rheumatoid arthritis. Rheumatology (Oxford, England). 50: 818-20. PMID 20663813 DOI: 10.1093/rheumatology/keq235 |
0.346 |
|
| 2010 |
Coenen MJ, Enevold C, Barrera P, Schijvenaars MM, Toonen EJ, Scheffer H, Padyukov L, Kastbom A, Klareskog L, Barton A, Kievit W, Rood MJ, Jansen TL, Swinkels D, van Riel PL, et al. Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. Plos One. 5: e14326. PMID 21179534 DOI: 10.1371/journal.pone.0014326 |
0.302 |
|
| 2010 |
Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology (Oxford, England). 49: 2154-64. PMID 20671022 DOI: 10.1093/rheumatology/keq195 |
0.313 |
|
| 2010 |
Fransen J, Visser K, van Dongen H, Huizinga T, van Riel PL, van der Heijde DM. Validity of the disease activity score in undifferentiated arthritis. Arthritis Care & Research. 62: 1392-8. PMID 20506371 DOI: 10.1002/acr.20244 |
0.323 |
|
| 2010 |
Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, Brus HL, van de Laar MA, van Riel PL. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care & Research. 62: 1335-41. PMID 20506128 DOI: 10.1002/acr.20211 |
0.324 |
|
| 2010 |
Schipper LG, Fransen J, den Broeder AA, Van Riel PL. Time to achieve remission determines time to be in remission. Arthritis Research & Therapy. 12: R97. PMID 20487520 DOI: 10.1186/ar3027 |
0.357 |
|
| 2010 |
Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 69: 1004-9. PMID 20447954 DOI: 10.1136/ard.2009.127225 |
0.316 |
|
| 2010 |
Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, ... ... van Riel P, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 69: 964-75. PMID 20444750 DOI: 10.1136/ard.2009.126532 |
0.386 |
|
| 2010 |
van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford, England). 49: 1294-302. PMID 20353956 DOI: 10.1093/rheumatology/keq043 |
0.303 |
|
| 2010 |
Enevold C, Radstake TR, Coenen MJ, Fransen J, Toonen EJ, Bendtzen K, van Riel PL. Multiplex screening of 22 single-nucleotide polymorphisms in 7 Toll-like receptors: an association study in rheumatoid arthritis. The Journal of Rheumatology. 37: 905-10. PMID 20194452 DOI: 10.3899/jrheum.090775 |
0.301 |
|
| 2010 |
Plantinga TS, Fransen J, Takahashi N, Stienstra R, van Riel PL, van den Berg WB, Netea MG, Joosten LA. Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritis. Arthritis Research & Therapy. 12: R26. PMID 20158887 DOI: 10.1186/ar2933 |
0.307 |
|
| 2010 |
Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA, Mariette X, Coenen MJ. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Annals of the Rheumatic Diseases. 69: 1022-8. PMID 19966089 DOI: 10.1136/Ard.2009.117622 |
0.357 |
|
| 2009 |
Schipper LG, Hoekstra M, Vliet Vlieland TP, Jansen TL, Lems WF, van Riel PL. Practice guideline 'Diagnosis and treatment of rheumatoid arthritis' | Richtlijn 'Diagnostiek en behandeling van reumatoïde artritis' Nederlands Tijdschrift Voor Geneeskunde. 153: A944. PMID 20051161 |
0.396 |
|
| 2009 |
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheumatic Diseases Clinics of North America. 35: 745-57, vii-viii. PMID 19962619 DOI: 10.1016/j.rdc.2009.10.001 |
0.321 |
|
| 2009 |
van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. The Journal of Rheumatology. 36: 2164-70. PMID 19723906 DOI: 10.3899/jrheum.081204 |
0.332 |
|
| 2009 |
Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. The Journal of Rheumatology. 36: 2171-7. PMID 19723902 DOI: 10.3899/jrheum.090054 |
0.312 |
|
| 2009 |
Burkhardt J, Petit-Teixeira E, Teixeira VH, Kirsten H, Garnier S, Ruehle S, Oeser C, Wolfram G, Scholz M, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Pascual-Salcedo D, ... ... Van Riel P, et al. Association of the X-chromosomal genes TIMP1 and IL9R with rheumatoid arthritis. The Journal of Rheumatology. 36: 2149-57. PMID 19723899 DOI: 10.3899/Jrheum.090059 |
0.527 |
|
| 2009 |
Coenen MJ, Trynka G, Heskamp S, Franke B, van Diemen CC, Smolonska J, van Leeuwen M, Brouwer E, Boezen MH, Postma DS, Platteel M, Zanen P, Lammers JW, Groen HJ, Mali WP, ... ... van Riel PL, et al. Common and different genetic background for rheumatoid arthritis and coeliac disease. Human Molecular Genetics. 18: 4195-203. PMID 19648290 DOI: 10.1093/Hmg/Ddp365 |
0.304 |
|
| 2009 |
Schipper LG, Fransen J, Barrera P, den Broeder AA, Van Riel PL. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? Rheumatology (Oxford, England). 48: 1247-53. PMID 19638454 DOI: 10.1093/rheumatology/kep158 |
0.407 |
|
| 2009 |
Schipper LG, Fransen J, Barrera P, Van Riel PL. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs. Rheumatology (Oxford, England). 48: 828-33. PMID 19458163 DOI: 10.1093/rheumatology/kep090 |
0.355 |
|
| 2009 |
Teixeira VH, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, et al. Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study. Arthritis Research & Therapy. 11: R45. PMID 19302705 DOI: 10.1186/ar2654 |
0.455 |
|
| 2009 |
Popa C, Netea MG, de Graaf J, van den Hoogen FH, Radstake TR, Toenhake-Dijkstra H, van Riel PL, van der Meer JW, Stalenhoef AF, Barrera P. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. The Journal of Rheumatology. 36: 724-30. PMID 19273452 DOI: 10.3899/jrheum.080626 |
0.371 |
|
| 2009 |
Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Annals of the Rheumatic Diseases. 68: 1739-45. PMID 19019895 DOI: 10.1136/ard.2008.092833 |
0.374 |
|
| 2009 |
Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL, Laan RF. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases. 68: 1470-3. PMID 19015210 DOI: 10.1136/ard.2008.094730 |
0.353 |
|
| 2009 |
Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, Fransen J. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Annals of the Rheumatic Diseases. 68: 1271-6. PMID 18701555 DOI: 10.1136/ard.2008.089862 |
0.35 |
|
| 2008 |
Dougados M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS, Aletaha D, van Riel P, Wells G. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Annals of the Rheumatic Diseases. 68: 484-9. PMID 19074177 DOI: 10.1136/ard.2008.092577 |
0.33 |
|
| 2008 |
Wagener FA, Toonen EJ, Wigman L, Fransen J, Creemers MC, Radstake TR, Coenen MJ, Barrera P, van Riel PL, Russel FG. HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis and Rheumatism. 58: 3388-93. PMID 18975324 DOI: 10.1002/art.23970 |
0.349 |
|
| 2008 |
van Lieshout AW, Creemers MC, Radstake TR, Elving LD, van Riel PL. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha. The Journal of Rheumatology. 35: 938-9. PMID 18464319 |
0.3 |
|
| 2008 |
ten Klooster PM, Veehof MM, Taal E, van Riel PL, van de Laar MA. Confirmatory factor analysis of the Arthritis Impact Measurement Scales 2 short form in patients with rheumatoid arthritis. Arthritis and Rheumatism. 59: 692-8. PMID 18438904 DOI: 10.1002/art.23569 |
0.347 |
|
| 2008 |
Toonen EJ, Coenen MJ, Kievit W, Fransen J, Eijsbouts AM, Scheffer H, Radstake TR, Creemers MC, de Rooij DJ, van Riel PL, Franke B, Barrera P. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Annals of the Rheumatic Diseases. 67: 1174-7. PMID 18385279 DOI: 10.1136/ard.2008.088138 |
0.346 |
|
| 2008 |
Toonen EJ, Barrera P, Radstake TR, van Riel PL, Scheffer H, Franke B, Coenen MJ. Gene expression profiling in rheumatoid arthritis: current concepts and future directions. Annals of the Rheumatic Diseases. 67: 1663-9. PMID 18250114 DOI: 10.1136/ard.2007.076588 |
0.312 |
|
| 2008 |
van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Annals of the Rheumatic Diseases. 67: 1697-701. PMID 18245109 DOI: 10.1136/ard.2007.083683 |
0.334 |
|
| 2008 |
Bruyn GA, Tate G, Caeiro F, Maldonado-Cocco J, Westhovens R, Tannenbaum H, Bell M, Forre O, Bjorneboe O, Tak PP, Abeywickrama KH, Bernhardt P, van Riel PL. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Annals of the Rheumatic Diseases. 67: 1090-5. PMID 18037627 DOI: 10.1136/ard.2007.078808 |
0.43 |
|
| 2008 |
Veehof MM, ten Klooster PM, Taal E, van Riel PL, van de Laar MA. Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases. 67: 789-93. PMID 17974597 DOI: 10.1136/ard.2007.081984 |
0.404 |
|
| 2008 |
Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van Riel P. Persistent severe fatigue in patients with rheumatoid arthritis. Journal of Clinical Nursing. 16: 377-83. PMID 17931330 DOI: 10.1111/j.1365-2702.2007.02082.x |
0.327 |
|
| 2007 |
van Riel PL, Fransen J. Established rheumatoid arthritis: clinical assessments. Best Practice & Research. Clinical Rheumatology. 21: 807-25. PMID 17870029 DOI: 10.1016/j.berh.2007.06.001 |
0.319 |
|
| 2007 |
Repping-Wuts H, Uitterhoeve R, van Riel P, van Achterberg T. Fatigue as experienced by patients with rheumatoid arthritis (RA): a qualitative study. International Journal of Nursing Studies. 45: 995-1002. PMID 17662291 DOI: 10.1016/j.ijnurstu.2007.06.007 |
0.319 |
|
| 2007 |
Alizadeh BZ, Valdigem G, Coenen MJ, Zhernakova A, Franke B, Monsuur A, van Riel PL, Barrera P, Radstake TR, Roep BO, Wijmenga C, Koeleman BP. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Human Molecular Genetics. 16: 2552-9. PMID 17652100 DOI: 10.1093/Hmg/Ddm194 |
0.301 |
|
| 2007 |
Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, ... ... Van Riel P, et al. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. Arthritis Research & Therapy. 9: R63. PMID 17615072 DOI: 10.1186/ar2221 |
0.53 |
|
| 2007 |
Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 66: 1503-7. PMID 17472994 DOI: 10.1136/ard.2006.066191 |
0.32 |
|
| 2007 |
ten Klooster PM, Veehof MM, Taal E, van Riel PL, van de Laar MA. Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. Annals of the Rheumatic Diseases. 66: 1485-90. PMID 17472993 DOI: 10.1136/ard.2007.069765 |
0.379 |
|
| 2007 |
Radstake TR, Fransen J, Toonen EJ, Coenen MJ, Eijsbouts AE, Donn R, van den Hoogen FH, van Riel PL. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. Annals of the Rheumatic Diseases. 66: 1525-30. PMID 17456524 DOI: 10.1136/ard.2006.064394 |
0.385 |
|
| 2007 |
Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Annals of the Rheumatic Diseases. 66: 1473-8. PMID 17426065 DOI: 10.1136/ard.2007.072447 |
0.378 |
|
| 2007 |
van Lieshout AW, Fransen J, Flendrie M, Eijsbouts AM, van den Hoogen FH, van Riel PL, Radstake TR. Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases. 66: 1334-8. PMID 17350968 DOI: 10.1136/ard.2006.066084 |
0.356 |
|
| 2007 |
Blom M, van Riel PL. Management of established rheumatoid arthritis with an emphasis on pharmacotherapy. Best Practice & Research. Clinical Rheumatology. 21: 43-57. PMID 17350543 DOI: 10.1016/j.berh.2006.09.002 |
0.344 |
|
| 2007 |
van Lieshout AW, Popa C, Meyer-Wentrup F, Lemmers HL, Stalenhoef AF, Adema GJ, van Riel PL, van Tits LJ, Radstake TR. Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. Biochemical and Biophysical Research Communications. 355: 392-7. PMID 17300746 DOI: 10.1016/j.bbrc.2007.01.161 |
0.343 |
|
| 2007 |
Michou L, Lasbleiz S, Rat AC, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Pierlot C, Glikmans E, Garnier S, Dausset J, Vaz C, Fernandes M, Petit-Teixeira E, ... ... Van Riel P, et al. Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene. Proceedings of the National Academy of Sciences of the United States of America. 104: 1649-54. PMID 17237219 DOI: 10.1073/Pnas.0610250104 |
0.535 |
|
| 2007 |
Flendrie M, Creemers MC, van Riel PL. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford, England). 46: 146-9. PMID 16782732 DOI: 10.1093/rheumatology/kel173 |
0.351 |
|
| 2006 |
Radstake TR, Franke B, Wenink MH, Nabbe KC, Coenen MJ, Welsing P, Bonvini E, Koenig S, van den Berg WB, Barrera P, van Riel PL. The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. Arthritis and Rheumatism. 54: 3828-37. PMID 17133580 DOI: 10.1002/art.22275 |
0.305 |
|
| 2006 |
Kievit W, Welsing PM, Adang EM, Eijsbouts AM, Krabbe PF, van Riel PL. Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. Arthritis and Rheumatism. 55: 745-50. PMID 17013821 DOI: 10.1002/art.22225 |
0.317 |
|
| 2006 |
Zandbelt MM, Houbiers JG, van den Hoogen FH, Meijerink J, van Riel PL, in't Hout J, van de Putte LB. Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis. The Journal of Rheumatology. 33: 1726-33. PMID 16960935 |
0.62 |
|
| 2006 |
Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases. 65: 1373-8. PMID 16644783 DOI: 10.1136/ard.2006.051706 |
0.375 |
|
| 2006 |
van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Annals of the Rheumatic Diseases. 65: 1478-83. PMID 16464988 DOI: 10.1136/ard.2005.043299 |
0.322 |
|
| 2005 |
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clinical and Experimental Rheumatology. 23: S93-9. PMID 16273792 |
0.319 |
|
| 2005 |
van Riel PL, Fransen J. DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis. Arthritis Research & Therapy. 7: 189-90. PMID 16207346 DOI: 10.1186/ar1820 |
0.415 |
|
| 2005 |
Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, Aletaha D, Anderson JJ, Bombardier C, Dougados M, Emery P, Felson DT, Fransen J, Furst DE, Hazes JM, ... ... van Riel PL, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. The Journal of Rheumatology. 32: 2016-24. PMID 16206362 |
0.376 |
|
| 2005 |
Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis and Rheumatism. 52: 3020-9. PMID 16200611 DOI: 10.1002/art.21285 |
0.304 |
|
| 2005 |
Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis and Rheumatism. 52: 2616-24. PMID 16142762 DOI: 10.1002/art.21259 |
0.387 |
|
| 2005 |
Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, Strand CV, Van Riel P, Smolen JS. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. The Journal of Rheumatology. 32: 1620-31. PMID 16078347 |
0.328 |
|
| 2005 |
van den Berg WB, van Riel PL. Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? Arthritis and Rheumatism. 52: 995-9. PMID 15818666 DOI: 10.1002/art.20981 |
0.3 |
|
| 2005 |
Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Annals of the Rheumatic Diseases. 64: 1195-8. PMID 15731289 DOI: 10.1136/ard.2004.032243 |
0.339 |
|
| 2005 |
Flendrie M, Creemers MC, Welsing PM, van Riel PL. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford, England). 44: 472-8. PMID 15598707 DOI: 10.1093/rheumatology/keh508 |
0.347 |
|
| 2005 |
Popa C, Netea MG, Radstake T, Van der Meer JW, Stalenhoef AF, van Riel PL, Barerra P. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 64: 303-5. PMID 15231512 DOI: 10.1136/ard.2004.023119 |
0.302 |
|
| 2005 |
Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Annals of the Rheumatic Diseases. 64: 127-9. PMID 15051621 DOI: 10.1136/Ard.2004.020503 |
0.643 |
|
| 2004 |
Fransen J, Laan RF, Van Der Laar MA, Huizinga TW, Van Riel PL. Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis. Annals of the Rheumatic Diseases. 63: 1222-6. PMID 15361375 DOI: 10.1136/ard.2003.018861 |
0.318 |
|
| 2004 |
Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, Swinkels HL, van der Heijde DM. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism. 50: 2082-93. PMID 15248205 DOI: 10.1002/art.20350 |
0.332 |
|
| 2004 |
Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford, England). 43: 1252-5. PMID 15238643 DOI: 10.1093/rheumatology/keh297 |
0.343 |
|
| 2004 |
Rau R, Simianer S, van Riel PL, van de Putte LB, Krüger K, Schattenkirchner M, Allaart CF, Breedveld FC, Kempeni J, Beck K, Kupper H. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scandinavian Journal of Rheumatology. 33: 145-53. PMID 15228184 |
0.52 |
|
| 2004 |
Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC. Lefunomide in combination therapy. The Journal of Rheumatology. Supplement. 71: 25-30. PMID 15170905 |
0.369 |
|
| 2004 |
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Annals of the Rheumatic Diseases. 63: 508-16. PMID 15082480 DOI: 10.1136/ard.2003.013052 |
0.567 |
|
| 2004 |
Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. The Journal of Rheumatology. Supplement. 69: 14-21. PMID 15053447 |
0.303 |
|
| 2004 |
Van Riel P. Leflunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. Clinical and Experimental Rheumatology. 21: 695-6. PMID 14740446 |
0.343 |
|
| 2003 |
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Annals of the Rheumatic Diseases. 62: 1168-77. PMID 14644854 |
0.554 |
|
| 2003 |
Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Annals of the Rheumatic Diseases. 62: ii30-3. PMID 14532145 |
0.367 |
|
| 2003 |
Barrera P, Oyen WJ, Boerman OC, van Riel PL. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 62: 825-8. PMID 12922953 |
0.323 |
|
| 2003 |
den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. The Netherlands Journal of Medicine. 61: 137-41. PMID 12852723 |
0.325 |
|
| 2003 |
de Vries N, Tak PP, Tijssen H, van Riel PL, van de Putte LB. Female sex increases risk for rheumatoid arthritis only in individuals encoding low-risk HLA-DRB1 alleles. Arthritis and Rheumatism. 48: 1762-3. PMID 12794845 DOI: 10.1002/art.11022 |
0.45 |
|
| 2003 |
Rau R, Sander O, Van Riel P, Van de Putte L, Hasler F, Zaug M, Kneer J, Van der Auwera P, Stevens RM, Baudin M, Dickson S, Herbold D, Kaehny MR, Luedin E, McAuliffe T. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): A double blind, placebo controlled dose-finding study in rheumatoid arthritis Journal of Rheumatology. 30: 680-690. PMID 12672184 |
0.552 |
|
| 2003 |
Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford, England). 42: 244-57. PMID 12595618 DOI: 10.1093/RHEUMATOLOGY/KEG072 |
0.318 |
|
| 2003 |
den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. The Journal of Rheumatology. 29: 2288-98. PMID 12415583 |
0.514 |
|
| 2002 |
Evers AW, Kraaimaat FW, van Riel PL, de Jong AJ. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. Pain. 100: 141-53. PMID 12435467 |
0.347 |
|
| 2002 |
Den Broeder AA, Creemers MC, van Gestel AM, van Riel PL. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford, England). 41: 638-42. PMID 12048289 |
0.31 |
|
| 2002 |
Fransen J, Stucki G, van Riel P. The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice? Rheumatology (Oxford, England). 41: 601-4. PMID 12048285 DOI: 10.1093/RHEUMATOLOGY/41.6.601 |
0.346 |
|
| 2002 |
Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford, England). 41: 430-9. PMID 11961174 |
0.534 |
|
| 2002 |
de Vries N, van Riel PL, van de Putte LB. Research in complex diseases. Lancet. 359: 1243-5. PMID 11955559 DOI: 10.1016/S0140-6736(02)08223-5 |
0.439 |
|
| 2002 |
de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis and Rheumatism. 46: 921-8. PMID 11953968 DOI: 10.1002/art.10210 |
0.514 |
|
| 2002 |
den Broeder AA, Joosten LA, Saxne T, Heinegård D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Annals of the Rheumatic Diseases. 61: 311-8. PMID 11874832 |
0.552 |
|
| 2001 |
Kroot EJ, van Gestel AM, Swinkels HL, Albers MM, van de Putte LB, van Riel PL. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. The Journal of Rheumatology. 28: 1511-7. PMID 11469455 |
0.56 |
|
| 2001 |
Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 60: 660-9. PMID 11406520 |
0.539 |
|
| 2001 |
Radstake TR, Barrera P, Albers MJ, Swinkels HL, van de Putte LB, van Riel PL. Genetic anticipation in rheumatoid arthritis in Europe. European Consortium on Rheumatoid Arthritis Families. The Journal of Rheumatology. 28: 962-7. PMID 11361223 |
0.55 |
|
| 2001 |
Laan RF, van Riel PL, van de Putte LB. Leflunomide and methotrexate. Current Opinion in Rheumatology. 13: 159-63. PMID 11333342 |
0.515 |
|
| 2001 |
Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van 't Hof MA, Schreuder FH, Leirisalo-Repo M, van Riel PL. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases. 60: 453-8. PMID 11302866 |
0.405 |
|
| 2000 |
Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, Van 't Hof MA, van De Putte LB, van Riel PL. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Annals of the Rheumatic Diseases. 59: 954-8. PMID 11087698 |
0.496 |
|
| 2000 |
Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism. 43: 1831-5. PMID 10943873 DOI: 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6 |
0.556 |
|
| 2000 |
Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, Klareskog L, Maini RN, Numo R, van De Putte LB, van Riel PL, Rodriguez-Valverde V. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Annals of the Rheumatic Diseases. 59: 504-5. PMID 10873957 DOI: 10.1136/ard.59.7.504 |
0.499 |
|
| 2000 |
Kuper IH, Prevoo ML, van Leeuwen MA, van Riel PL, Lolkema WF, Postma DS, van Rijswijk MH. Disease associated time consumption in early rheumatoid arthritis. The Journal of Rheumatology. 27: 1183-9. PMID 10813285 |
0.332 |
|
| 2000 |
Radstake TR, Barrera P, Albers JM, Swinkels HL, van de Putte LB, van Riel PL. Familial vs sporadic rheumatoid arthritis (RA). A prospective study in an early RA inception cohort. Rheumatology (Oxford, England). 39: 267-73. PMID 10788534 |
0.553 |
|
| 2000 |
van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de Putte LB. Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. The Journal of Rheumatology. 27: 535-8; discussion 53. PMID 10685829 |
0.461 |
|
| 2000 |
Jacobs JW, Blaauw AA, Dijkmans BA, van Riel PL, Bijlsma JW. [Pharmacotherapy of patients with (early) rheumatoid arthritis]. Nederlands Tijdschrift Voor Geneeskunde. 144: 211-6. PMID 10682647 |
0.367 |
|
| 1999 |
Kroot EJ, van de Putte LB, van Riel PL. Management of therapy-resistant rheumatoid arthritis. Bailliã¨Re's Best Practice & Research. Clinical Rheumatology. 13: 737-52. PMID 10652651 DOI: 10.1053/berh.1999.0057 |
0.568 |
|
| 1999 |
van Riel PL, Haagsma CJ, Furst DE. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. Bailliã¨Re's Best Practice & Research. Clinical Rheumatology. 13: 689-700. PMID 10652648 DOI: 10.1053/berh.1999.0054 |
0.372 |
|
| 1999 |
van de Putte LB, Kroot EJ, van Riel PL. Management of refractory rheumatoid arthritis. Rheumatology (Oxford, England). 38: 32-4. PMID 10646488 |
0.572 |
|
| 1999 |
de Vries N, van Elderen C, Tijssen H, van Riel PL, van de Putte LB. No support for HLA-DQ encoded susceptibility in rheumatoid arthritis. Arthritis and Rheumatism. 42: 1621-7. PMID 10446860 DOI: 10.1002/1529-0131(199908)42:8<1621::AID-ANR9>3.0.CO;2-0 |
0.495 |
|
| 1999 |
Albers JM, Kuper HH, van Riel PL, Prevoo ML, van 't Hof MA, van Gestel AM, Severens JL. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford, England). 38: 423-30. PMID 10371280 |
0.304 |
|
| 1999 |
Barrera P, Radstake TR, Albers JM, van Riel PL, van de Putte LB. Familial aggregation of rheumatoid arthritis in The Netherlands: a cross-sectional hospital-based survey. European Consortium on Rheumatoid Arthritis families (ECRAF). Rheumatology (Oxford, England). 38: 415-22. PMID 10371279 |
0.535 |
|
| 1999 |
Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, van de Putte LB. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 58: 79-84. PMID 10343521 |
0.501 |
|
| 1999 |
Laan RF, Jansen TL, van Riel PL. Glucocorticosteroids in the management of rheumatoid arthritis. Rheumatology (Oxford, England). 38: 6-12. PMID 10334676 |
0.31 |
|
| 1999 |
van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, Wells G, Lange ML, Felson DT. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. The Journal of Rheumatology. 26: 705-11. PMID 10090187 |
0.347 |
|
| 1999 |
Kuper IH, van Leeuwen MA, van Riel PL, Sluiter WJ, Houtman NM, Cats HA, van Rijswijk MH. Influence of a ceiling effect on the assessment of radiographic progression in rheumatoid arthritis during the first 6 years of disease. The Journal of Rheumatology. 26: 268-76. PMID 9972957 |
0.348 |
|
| 1998 |
van de Putte LB, van Gestel AM, van Riel PL. Early treatment of rheumatoid arthritis: rationale, evidence, and implications. Annals of the Rheumatic Diseases. 57: 511-2. PMID 9849307 |
0.558 |
|
| 1998 |
van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis and Rheumatism. 41: 1845-50. PMID 9778226 DOI: 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K |
0.344 |
|
| 1997 |
Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. British Journal of Rheumatology. 36: 1082-8. PMID 9374925 |
0.61 |
|
| 1997 |
van de Putte LB, van Riel PL. Currently used second-line agents: do they control the disease course? Clinical and Experimental Rheumatology. 15: S71-4. PMID 9266136 |
0.546 |
|
| 1997 |
van Gestel AM, Haagsma CJ, Furst DE, van Riel PL. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Bailliã¨Re's Clinical Rheumatology. 11: 65-82. PMID 9088525 |
0.315 |
|
| 1997 |
van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB, Pepys MB, Limburg PC. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. The Journal of Rheumatology. 24: 20-7. PMID 9002006 |
0.515 |
|
| 1996 |
Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology. 35: 1101-5. PMID 8948296 |
0.551 |
|
| 1996 |
van Riel PL, van Gestel AM, van de Putte LB. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. British Journal of Rheumatology. 35: 4-7. PMID 8810683 |
0.555 |
|
| 1996 |
Creemers MC, van 't Hof MA, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL. Disease activity in ankylosing spondylitis: selection of a core set of variables and a first set in the development of a disease activity score. British Journal of Rheumatology. 35: 867-73. PMID 8810670 DOI: 10.1093/Rheumatology/35.9.867 |
0.658 |
|
| 1995 |
Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL. Methotrexate in severe ankylosing spondylitis: an open study. The Journal of Rheumatology. 22: 1104-7. PMID 7674237 |
0.712 |
|
| 1994 |
Creemers MC, Van 't Hof MA, Franssen MJ, Van de Putte LB, Gribnau FW, Van Riel PL. A Dutch version of the functional index for ankylosing spondylitis: development and validation in a long-term study. British Journal of Rheumatology. 33: 842-6. PMID 8081670 DOI: 10.1093/Rheumatology/33.9.842 |
0.685 |
|
| 1994 |
Barrera P, Van Ede A, Laan RF, Van Riel PL, Boerbooms AM, Van De Putte LB. Methotrexate-related pulmonary complications in patients with rheumatoid arthritis: cluster of five cases in a period of three months. Annals of the Rheumatic Diseases. 53: 479-80. PMID 7944625 |
0.492 |
|
| 1994 |
Russel FG, Creemers MC, Tan Y, van Riel PL, Gribnau FW. Ion-pair solid-phase extraction of cimetidine from plasma and subsequent analysis by high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Applications. 661: 173-7. PMID 7866547 DOI: 10.1016/0378-4347(94)00320-3 |
0.517 |
|
| 1994 |
Creemers MC, van Riel PL, Franssen MJ, van de Putte LB, Gribnau FW. Second-line treatment in seronegative spondylarthropathies. Seminars in Arthritis and Rheumatism. 24: 71-81. PMID 7839156 DOI: 10.1016/S0049-0172(05)80001-0 |
0.67 |
|
| 1993 |
Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Annals of Internal Medicine. 119: 963-8. PMID 8105737 DOI: 10.7326/0003-4819-119-10-199311150-00001 |
0.491 |
|
| 1991 |
Jacobs JW, Rasker JJ, Van Riel PL, Gribnau FW, van de Putte LB. [Alternative treatment methods in rheumatic diseases; a literature review]. Nederlands Tijdschrift Voor Geneeskunde. 135: 317-22. PMID 2008219 |
0.698 |
|
| 1991 |
Jacobs JW, Rasker JJ, van Riel PL, Gribnau FW, van de Putte LB. Rheumajecta and vasolastine in the treatment of rheumatoid arthritis--the results of a placebo-controlled, double-blind trial of a complementary treatment. Scandinavian Journal of Rheumatology. 20: 434-40. PMID 1771401 DOI: 10.3109/03009749109096823 |
0.73 |
|
| 1991 |
Wijnands MJ, Nuver-Zwart IH, van Riel PL, van 't Hof MA, Gribnau FW, van De Putte LB. Hemolysis during low-dose sulfasalazine treatment in rheumatoid arthritis patients. Scandinavian Journal of Rheumatology. 20: 52-7. PMID 1672775 DOI: 10.3109/03009749109165922 |
0.72 |
|
| 1990 |
Wijnands MJ, van Riel PL, Gribnau FW, van de Putte LB. [Risk factors for the development of side effects during treatment of rheumatoid arthritis with second-line antirheumatic agents; a review of the literature]. Nederlands Tijdschrift Voor Geneeskunde. 134: 1387-91. PMID 2197565 |
0.689 |
|
| 1990 |
Wijnands MJ, van Riel PL, Gribnau FW, van de Putte LB. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 19: 337-52. PMID 2196675 DOI: 10.1016/0049-0172(90)90071-M |
0.671 |
|
| 1990 |
Jacobs JW, Rasker JJ, van Riel PL, Gribnau FW, van de Putte LB. [Rheumajecta and Vasolastine treatment of primary fibromyalgia; results of a randomized placebo-controlled double-blind study]. Nederlands Tijdschrift Voor Geneeskunde. 134: 693-7. PMID 2157988 |
0.642 |
|
| 1990 |
Wijnands MJ, Allebes WA, Boerbooms AM, van de Putte LB, van Riel PL. Thrombocytopenia due to aurothioglucose, sulphasalazine, and hydroxychloroquine. Annals of the Rheumatic Diseases. 49: 798-800. PMID 1978639 |
0.489 |
|
| 1989 |
Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Annals of the Rheumatic Diseases. 48: 389-95. PMID 2567150 DOI: 10.1136/Ard.48.5.389 |
0.722 |
|
| 1989 |
van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1: 1036-8. PMID 2565997 |
0.658 |
|
| 1988 |
van Riel PL, Nuver-Zwart HH, van de Putte LB, Gribnau FW. [Sulfasalazine as an antirheumatism agent; a review of the literature]. Nederlands Tijdschrift Voor Geneeskunde. 132: 594-5. PMID 2896302 |
0.609 |
|
| 1987 |
Van Riel PL, Gribnau FW, Van de Putte LB, Arts CW, Van Aernsbergen A. Serum gold concentrations during treatment with auranofin. Clinical Rheumatology. 6: 50-4. PMID 3581698 DOI: 10.1007/Bf02201000 |
0.668 |
|
| 1986 |
Van Riel PL, Larsen A, Van de Putte LB, Gribnau FW. Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis. Clinical Rheumatology. 5: 359-64. PMID 3096626 DOI: 10.1007/Bf02054254 |
0.661 |
|
| 1984 |
van Riel PL, van de Putte LB, Gribnau FW, de Waal RM. IgA deficiency during aurothioglucose treatment. A case report. Scandinavian Journal of Rheumatology. 13: 334-6. PMID 6441247 DOI: 10.3109/03009748409111305 |
0.66 |
|
| 1984 |
van Riel PL, van de Putte LB, Gribnau FW, Macrae KD. Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study. Clinical Rheumatology. 3: 51-6. PMID 6432414 DOI: 10.1007/Bf03342622 |
0.68 |
|
| 1984 |
Van Riel PL, van de Putte LB, Gribnau FW, de Waal RM. Serum IgA and gold-induced toxic effects in patients with rheumatoid arthritis. Archives of Internal Medicine. 144: 1401-3. PMID 6428342 DOI: 10.1001/Archinte.144.7.1401 |
0.652 |
|
| 1983 |
van Riel PL, Reekers P, van de Putte LB, Gribnau FW. Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens. 22: 194-9. PMID 6415865 DOI: 10.1111/J.1399-0039.1983.Tb01191.X |
0.691 |
|
| 1983 |
van Riel PL, Gribnau FW, van de Putte LB. Cell-bound gold (CBG) in patients treated with aurothioglucose and with auranofin. A comparison of different methods of determination. The Journal of Rheumatology. 10: 574-8. PMID 6413685 |
0.604 |
|
| 1983 |
van Riel PL, Gribnau FW, van de Putte LB, Yap SH. Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities. The Journal of Rheumatology. 10: 222-6. PMID 6408256 |
0.596 |
|
| Show low-probability matches. |
